Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
947 participants
INTERVENTIONAL
2007-11-30
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
NCT00425100
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
NCT01302067
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
NCT00911937
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
NCT00561951
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
NCT00220363
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fesoterodine 4mg or 8mg
Fesoterodine
Fesoterodine 4mg or 8mg
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fesoterodine
Fesoterodine 4mg or 8mg
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On a stable and well-tolerated dose of an alpha-blocker prescribed for LUTS for at least 6 weeks prior to screening (Visit 1).
* Persistent symptoms of OAB with urinary frequency \>=8 times/24 hours and micturition-related urgency episodes \>=3 episode/24 hours.
Exclusion Criteria
* Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.
* Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer,Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Litchfield Park, Arizona, United States
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
La Mesa, California, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
San Bernardino, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Jupiter, Florida, United States
Pfizer Investigational Site
Orange City, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Dunwoody, Georgia, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Jeffersonville, Indiana, United States
Pfizer Investigational Site
Newburgh, Indiana, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Owings Mills, Maryland, United States
Pfizer Investigational Site
Watertown, Massachusetts, United States
Pfizer Investigational Site
Flint, Michigan, United States
Pfizer Investigational Site
Saint Clair Shores, Michigan, United States
Pfizer Investigational Site
Troy, Michigan, United States
Pfizer Investigational Site
Utica, Michigan, United States
Pfizer Investigational Site
West Bloomfield, Michigan, United States
Pfizer Investigational Site
West Bloomfield, Michigan, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Sewell, New Jersey, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Garden City, New York, United States
Pfizer Investigational Site
Kingston, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Poughkeepsie, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Greensboro, North Carolina, United States
Pfizer Investigational Site
Fargo, North Dakota, United States
Pfizer Investigational Site
Fargo, North Dakota, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Bethany, Oklahoma, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Bala-Cynwyd, Pennsylvania, United States
Pfizer Investigational Site
Camp Hill, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Greer, South Carolina, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Madison, Wisconsin, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Antwerp, , Belgium
Pfizer Investigational Site
Edegem, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Salvador, Estado de Bahia, Brazil
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
Campos do Jordão, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Barrie, Ontario, Canada
Pfizer Investigational Site
North Bay, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Göttingen, , Germany
Pfizer Investigational Site
Hagenow, , Germany
Pfizer Investigational Site
Lauenburg, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Oberursel, , Germany
Pfizer Investigational Site
Wiesbaden, , Germany
Pfizer Investigational Site
Ioannina, Ipiros, Greece
Pfizer Investigational Site
Pátrai, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
New Delhi, New Delhi, India
Pfizer Investigational Site
Ludhiana, Punjab, India
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India
Pfizer Investigational Site
Kuching, Sarawak, Malaysia
Pfizer Investigational Site
Kuching, Sarawak, Malaysia
Pfizer Investigational Site
Roermond, , Netherlands
Pfizer Investigational Site
Tilburg, , Netherlands
Pfizer Investigational Site
Zutphen, , Netherlands
Pfizer Investigational Site
Bodø, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Cebu City, Cebu, Philippines
Pfizer Investigational Site
Quezon City, Philippines, Philippines
Pfizer Investigational Site
Bacolod City, , Philippines
Pfizer Investigational Site
Makati City, , Philippines
Pfizer Investigational Site
Manila, , Philippines
Pfizer Investigational Site
Manila, , Philippines
Pfizer Investigational Site
Bialystok, , Poland
Pfizer Investigational Site
Gdansk, , Poland
Pfizer Investigational Site
Gdansk, , Poland
Pfizer Investigational Site
Lodz, , Poland
Pfizer Investigational Site
Mysłowice, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Singapore, Singapore, Singapore
Pfizer Investigational Site
Singapore, Singapore, Singapore
Pfizer Investigational Site
Bratislava, Slovakia, Slovakia
Pfizer Investigational Site
Martin, Slovakia, Slovakia
Pfizer Investigational Site
Piešťany, Slovakia, Slovakia
Pfizer Investigational Site
Banská Bystrica, , Slovakia
Pfizer Investigational Site
Skalica, , Slovakia
Pfizer Investigational Site
Bucheon-si, Gyunggi-do, South Korea
Pfizer Investigational Site
Pusan, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Martorell, Barcelona, Spain
Pfizer Investigational Site
Getafe, Madrid, Spain
Pfizer Investigational Site
Manacor, Palma de Mallorca, Spain
Pfizer Investigational Site
Borås, , Sweden
Pfizer Investigational Site
Jönköping, , Sweden
Pfizer Investigational Site
Skövde, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Ratchathewi, Bangkok, Thailand
Pfizer Investigational Site
Amphoe Mueang, Chiang Mai, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0221009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.